KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bionano Genomics (BNGO) EBT (2017 - 2025)

Historic EBT for Bionano Genomics (BNGO) over the last 9 years, with Q3 2025 value amounting to -$8.5 million.

  • Bionano Genomics' EBT rose 8080.37% to -$8.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$38.6 million, marking a year-over-year increase of 7160.63%. This contributed to the annual value of -$112.0 million for FY2024, which is 5182.05% up from last year.
  • As of Q3 2025, Bionano Genomics' EBT stood at -$8.5 million, which was up 8080.37% from -$6.8 million recorded in Q2 2025.
  • Bionano Genomics' 5-year EBT high stood at -$3.1 million for Q1 2025, and its period low was -$112.5 million during Q3 2023.
  • Over the past 5 years, Bionano Genomics' median EBT value was -$29.9 million (recorded in 2022), while the average stood at -$30.1 million.
  • In the last 5 years, Bionano Genomics' EBT crashed by 25407.0% in 2023 and then soared by 9015.59% in 2025.
  • Over the past 5 years, Bionano Genomics' EBT (Quarter) stood at -$28.7 million in 2021, then dropped by 28.4% to -$36.9 million in 2022, then decreased by 19.13% to -$43.9 million in 2023, then skyrocketed by 54.19% to -$20.1 million in 2024, then skyrocketed by 57.82% to -$8.5 million in 2025.
  • Its last three reported values are -$8.5 million in Q3 2025, -$6.8 million for Q2 2025, and -$3.1 million during Q1 2025.